Ethics & Informed Consent: Retrospective Case-Control Study (Spain)

1. Ethical Principles & Legislative Framework

In research involving human participants, securing ethical clearance is a critical first step. For a Retrospective Case-Control Study being conducted in Spain, study designs must align with the primary regulatory legislation: Royal Decree 1090/2015 on Clinical Trials. This statutory framework ensures participant welfare, confidentiality, and voluntary involvement are protected.

Administrative review and formal approval are managed by a local or regional Comité de Ética de la Investigación con medicamentos (CEIm). Researchers must secure full approval or a formal exemption certificate from this board before recruiting any participants or commencing data collection.

2. Study Design Elements & Reporting Integrity

For a Retrospective Case-Control Study, the review board places significant focus on methodological transparency. The application must outline the research rationale, recruitment protocols, inclusion and exclusion criteria, and data protection measures.

Study Classification: Minimal Risk (Exempt or Expedited)

Case-control studies rely on historical data extraction. When active consent is unfeasible, a waiver can be requested by proving secure de-identification and minimal participant risk.

To guarantee academic integrity and reproducibility, the study report and subsequent publications should follow the internationally recognised reporting standard: STROBE guidelines.

3. Informed Consent & Information Sheet Guidelines

A robust participant information sheet and informed consent form are critical parts of the ethical application. Ensure your documentation incorporates the following components:

• Plain Language Explanations: Avoid complex medical or technical terminology. Ensure readability matches the general population.
• Voluntary Participation: Explicitly state that participation is entirely voluntary and that individuals can withdraw at any time without negative consequences.
• Confidentiality & Data Controls: Explain how participant data will be anonymised or pseudonymised, who will have access to it, and how long it will be securely retained under EU GDPR & Organic Law 3/2018 on Personal Data Protection (LOPDGDD).
• Risk/Benefit Disclosure: Clearly list any potential risks, discomforts, or direct benefits associated with participation in the study.
• Ethics Board Contact Information: Provide the contact details of the reviewing Comité de Ética de la Investigación con medicamentos (CEIm) so participants can reach out if they have questions or concerns.

Research Ethics, Clinical Trials & Institutional Governance

Conducting data collection for this observational Retrospective Case-Control Study in Spain requires addressing passive ethical considerations in research. Ensuring database security is essential when the study involves vulnerable populations research ethics protections. Every registered subject must review a comprehensive research consent form that explains how records are linked and stored. The PI must secure formal institutional review board approval from the Comité de Ética de la Investigación con medicamentos (CEIm) before extracting any clinical records. Observational cohorts retrieving biospecimens must declare their laboratory safety ratings from biosafety level 1 2 3 4. Ethical oversight committees in Spain audit the study's consent registry periodically to verify compliance with national legal statutes.

4. Regulatory Checklist Table

To streamline your ethical review submission, use the structured alignment checklist below:

6. Frequently Asked Questions